Are there alternatives to ibrutinib/ibrutinib?

With the U.S. Food and Drug Administration (FDA) approving the BTK inhibitor Acalabrutinib in November 2019, the treatment prospects for chronic lymphocytic leukemia (CLL) have been expanded. Another BTK inhibitor, ibrutinib, was already approved in this setting, and the FDA expanded the indication in April 2020 to include first-line treatment of all adult patients with chronic lymphocytic leukemia.

While ibrutinib is associated with favorable outcomes in patients with chronic lymphocytic leukemia, its toxicity can be a challenge for patients. This provides a role for acotinib in patients who cannot tolerate ibrutinib, as this drug has a different toxicity profile. Akolitinib is a BTK inhibitor recently approved for first-line treatment and relapsed/refractory CLL. The previously marketed BTK inhibitor ibrutinib differs in that it may have different toxicities. In a real-world analysis published in 2019, real-world results of acotinib in patients with CLL were reviewed to determine benefit in a more realistic patient population. Overall, the researchers noted that patients who did not tolerate ibrutinib had lower discontinuation rates with acotinib, suggesting that the drug is a well-tolerated alternative to ibrutinib for patients who may benefit from BTK inhibition but cannot tolerate ibrutinib-related toxicity.

However, each patient's situation is different, and whether and how to use acotinib needs to be decided on a case-by-case basis. These decisions should be evaluated by a professional physician and the best treatment plan based on the patient's condition, resistance mechanisms, and personal health.